Reminyl® (galantamine hydrobromide): New warning on serious skin reactions (Stevens Johnson syndrome and acute generalised exanthematous pustulosis)

Janssen, a division of Johnson & Johnson Pte Ltd, would like to alert healthcare professionals to the risk of serious skin reactions that have been reported with the use of Reminyl® (galantamine hydrobromide). Stevens Johnson syndrome (SJS) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving Reminyl®. Patients should be informed about the signs of serious skin reactions, and that use of Reminyl® should be discontinued at the first appearance of skin rash. These warnings regarding serious skin reactions are in the process of being updated in the Reminyl® Singapore package insert, with SJS and AGEP to be included as new adverse reactions. Please refer to the letter for more information.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.